Recombinant Interleukin-2

DRUG2 trials

Sponsors

BZL Biologics, Case Western Reserve University

Conditions

HIV InfectionProstatic Neoplasms

Phase 2

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

CompletedNCT00040586

BZL BiologicsProstatic Neoplasms

Updated: 2007-01-22

HIV Reservoir Reduction With Interleukin-2

TerminatedNCT03308786

Case Western Reserve UniversityHIV Infection

Start: 2019-04-01End: 2020-08-20Updated: 2022-09-28